When Gilead acquired CAR-T leader Kite Pharma, it made a crucial decision not to fully integrate it. This preserved Kite's distinct, individualized therapy operating model, which is fundamentally different from a traditional "off-the-shelf" drug company, proving a key lesson in M&A strategy for novel platforms.
Related Insights
When a large company acquires a startup, the natural tendency is to impose its standardized processes. Successful integration requires a balance: knowing which systems to standardize for leverage while allowing the acquired team to maintain its freewheeling, startup-style execution.
Successful large-scale acquirers remain nimble, flexing their own processes to suit the acquired company rather than force-fitting it into a rigid corporate structure. This preserves the culture and talent that made the company valuable, preventing value destruction and keeping the new team engaged.
The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.
When integrating acquired biotechs, Merck prioritizes retaining key talent and preserving ongoing science. The strategy involves immediate face-to-face engagement to reduce anxiety, followed by a pragmatic assessment of which processes must be standardized versus which can remain to avoid disrupting critical trials, a practice they call avoiding 'mercification'.
A one-size-fits-all integration can destroy the culture that made an acquisition valuable. When State Street acquired software firm CRD, it intentionally broke from its standard process, allowing CRD to keep its brand identity, facilities, and even email domain to preserve its creative culture and retain key talent.
M&A is often framed as a win, but it can be detrimental to patients. The acquisition of an aggressive, fast-moving biotech by a large pharma company can lead to slowed development timelines and more conservative regulatory strategies, ultimately delaying access to life-saving treatments.
Experienced acquirers mistakenly believe a standard template can apply to all carve-out deals. However, since every company's internal operations are bespoke, a template is at best 80% accurate. The remaining 20% requires deep, deal-specific analysis to avoid unforeseen integration challenges and costs, making over-reliance on a template a significant risk.
The current biotech M&A boom is less about frantically plugging near-term patent cliff gaps (e.g., 2026-2027) and more about building long-term, strategic franchises. This forward-looking approach allows big pharma to acquire earlier-stage platforms and assets, signaling a healthier, more sustainable M&A environment.
For certain acquisitions like Poker, IFS deliberately avoids full integration to retain the target's agile, entrepreneurial culture. Instead, they use product connectors and provide access to parent company resources, allowing the startup to maintain its dynamism while leveraging scale.
A key to M&A success is creating a founder-friendly environment. Avoid killing entrepreneurial spirit by forcing founders into a rigid matrix organization. Instead, maintain the structures that made them successful and accelerate them by providing resources from the parent company.
